Related Experiment Video

Updated: Nov 18, 2025

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

13.8K

G3BP1 promotes human breast cancer cell proliferation through coordinating with GSK-3β and stabilizing β-catenin

Cong-Hui Zhang1, Hong Liu1, Wu-Li Zhao1

  • 1Key Laboratory of Antibiotic Bioengineering, Ministry of Health, Laboratory of Oncology, Institute of Medicinal Biotechnology, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, 100050, China.

Acta Pharmacologica Sinica
|February 4, 2021
PubMed

Insights

Ras-GTPase activating SH3 domain-binding protein 1 (G3BP1) is upregulated in breast cancer, promoting cell proliferation by stabilizing beta-catenin. Targeting the G3BP1/GSK-3beta/beta-catenin pathway may offer new breast cancer therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Ras-GTPase activating SH3 domain-binding protein 1 (G3BP1) is implicated in various human cancers.
  • The specific role of G3BP1 in breast cancer progression is not well understood.

Purpose of the Study:

  • To investigate the role and mechanism of G3BP1 in breast cancer.
  • To explore G3BP1 as a potential therapeutic target for breast cancer.

Main Methods:

  • Analysis of G3BP1 expression levels and correlation with patient prognosis.
  • Investigation of G3BP1's effect on breast cancer cell proliferation and beta-catenin signaling.
  • Examination of G3BP1's interaction with GSK-3beta and its impact on beta-catenin stability.

Main Results:

  • G3BP1 is upregulated in breast cancer and associated with poor prognosis.
  • G3BP1 overexpression enhances breast cancer cell proliferation via beta-catenin signaling.
  • G3BP1 stabilizes beta-catenin by inhibiting its degradation and inactivating GSK-3beta.
  • Disruption of the G3BP1-GSK-3beta interaction reduces breast cancer cell proliferation.

Conclusions:

  • The G3BP1/GSK-3beta/beta-catenin axis is a key regulator of breast cancer progression.
  • G3BP1 promotes breast cancer cell proliferation by stabilizing beta-catenin.
  • This regulatory axis represents a potential therapeutic target for breast cancer treatment.
Keywords:
G3BP1GSK-3β phosphorylationWnt/β-catenin signaling pathwaybreast cancerpeptide antagonistprotein stability

More Related Videos

Visualization of G3BP Stress Granules Dynamics in Live Primary Cells10:12

Visualization of G3BP Stress Granules Dynamics in Live Primary Cells

Published on: May 21, 2014

18.6K
Spheroid Assay to Measure TGF-β-induced Invasion09:18

Spheroid Assay to Measure TGF-β-induced Invasion

Published on: November 16, 2011

22.2K

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
8.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.9K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
37.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.3K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.7K